1. Show article details.

    BRIEF-Eli Lilly Says Combining Lilly Research Laboratories Oncology Organization And Loxo Oncology

    Reuters – 6:34 AM ET 12/05/2019

    Eli Lilly and Co (LLY): * LILLY ANNOUNCES NEW LEADERSHIP AND STRATEGY IN ONCOLOGY RESEARCH AND DEVELOPMENT. * Eli Lilly and Co (LLY) - NEW ORGANIZATION, NAMED LOXO ONCOLOGY AT LILLY, WILL BE LED JOINTLY BY JOSH BILENKER, JACOB VAN NAARDEN, AND NISHA NANDA. * Eli Lilly and Co (LLY) - COMBINING LILLY RESEARCH LABORATORIES ONCOLOGY ORGANIZATION AND LOXO ONCOLOGY Source text for Eikon: Further company coverage:

  2. Show article details.

    Eli Lilly to put Loxo executives in charge of new cancer research unit

    Reuters – 6:30 AM ET 12/05/2019

    U.S. drugmaker Eli Lilly and Co (LLY) said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year. The move highlights Lilly's efforts to double down on its cancer business following the $8 billion acquisition of Loxo in February.

  3. Show article details.

    Lilly Announces New Leadership and Strategy in Oncology Research and Development

    PR Newswire – 6:30 AM ET 12/05/2019

    INDIANAPOLIS, Dec. 5, 2019 Eli Lilly and Company (LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019.

  4. Show article details.

    Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference

    PR Newswire – 4:33 PM ET 12/02/2019

    INDIANAPOLIS, Dec. 2, 2019  Eli Lilly and Company (LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:30 a.m., Eastern Time.

  5. Show article details.

    Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco

    PR Newswire – 9:00 AM ET 12/02/2019

    INDIANAPOLIS, Dec. 2, 2019  Eli Lilly and Company (LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies.

  6. Show article details.

    Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)

    PR Newswire – 7:22 AM ET 12/02/2019

    INDIANAPOLIS, Dec. 2, 2019  Eli Lilly and Company's first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease," has concluded, with HealthVoyager, an application developed by Boston Children's Hospital and Klick Health, being named the winner.

  7. Show article details.

    China to use drug bulk-buy program to close price gap

    Reuters – 10:47 AM ET 11/30/2019

    China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.

  8. Show article details.

    Drugmakers slash prices in China to get on reimbursement list

    Reuters – 1:50 AM ET 11/28/2019

    Drugmakers including Roche and Novartis' have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

  9. Show article details.

    Advanced Medical Technologies Help Stem the Evergrowing Spread of Ailments

    PR Newswire – 9:00 AM ET 11/26/2019

    PALM BEACH, Florida, Nov. 26, 2019 In 2017, the Institute for Health Metrics and Evaluation said in a report that a total of 359 diseases and injuries were added to the fatal and non-fatal list of conditions since 1950. Notably, kidney diseases are one of the most common diseases in the U.S., affecting nearly 37 million people, according to the National Kidney Foundation.

  10. Show article details.

    BRIEF-Eli Lilly And Co Says 10% Owner Lilly Endowment Reports Open Market Sale Of 108,264 Shares Of Co's Common Stock

    Reuters – 11:05 AM ET 11/22/2019

    Eli Lilly and Co (LLY): * ELI LILLY AND CO SAYS 10% OWNER LILLY ENDOWMENT REPORTS OPEN MARKET SALE OF 108,264 SHARES OF CO'S COMMON STOCK IN MULTIPLE TRANSACTIONS - SEC FILING. * ELI LILLY AND CO SAYS LILLY ENDOWMENT REPORTS OPEN MARKET TRANSACTIONS ON NOVEMBER 21, IN PRICE RANGE BETWEEN $115.00 TO $115.51 PER SHARE Source text : Further company coverage:

  11. Show article details.

    Patients Seek Non-Opioid Options for Cancer Pain Management

    PR Newswire – 9:00 AM ET 11/20/2019

    NEW YORK, Nov. 20, 2019 In 2019, the American Cancer Society is estimating a total of 1.76 million new cancer cases and 606,880 cancer-related deaths in the U.S. The National Cancer Institute expects prostate, lung, breast, and colon/rectal cancer to account for the majority of the new estimated cases.

  12. Show article details.

    China plans to add more drugs to price-slashing bulk-buy program

    Reuters – 8:57 AM ET 11/20/2019

    China will add more drugs to its bulk-buy program in an effort to curb high medicine prices, the country's cabinet said, in a move that could increase downwards price pressure on multinational pharmaceuticals' off-patent established products.

  13. Show article details.

    Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus

    MarketWatch – 7:09 AM ET 11/20/2019

    Eli Lilly& Co. said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result of increased demand for its medicines and for the production of additional capacity for future medicines, and are helped by having more capital available as a result of tax reform. "These investments support our manufacturing capabilities in Indianapolis,...

  14. Show article details.

    BRIEF-Lilly Announces $400 Mln Capital Investment In Manufacturing Facilities In Indianapolis

    Reuters – 6:44 AM ET 11/20/2019

    Eli Lilly and Co (LLY): * LILLY ANNOUNCES $400 MILLION CAPITAL INVESTMENT IN MANUFACTURING FACILITIES IN INDIANAPOLIS. * Eli Lilly and Co (LLY) - NEW INVESTMENTS AT LILLY TECHNOLOGY CENTER CAMPUS WILL CREATE ABOUT 100 NEW HIGHLY SKILLED JOBS AT CO Source text for Eikon: Further company coverage:

  15. Show article details.

    Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis

    PR Newswire – 6:30 AM ET 11/20/2019

    INDIANAPOLIS, Nov. 20, 2019  Eli Lilly and Company (LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by increasing demand for Lilly's current medicines, and they provide additional manufacturing capacity for future medicines coming from Lilly's pipeline.

  16. Show article details.

    Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement

    PR Newswire – 4:15 PM ET 11/19/2019

    INDIANAPOLIS, Nov. 19, 2019 Eli Lilly and Company (LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance. The conference call will begin at 9 a.m. Eastern time.

  17. Show article details.

    BRIEF-Eli Lilly Says Interim Analysis From Emprise Real-World Study Shows Jardiance Decreased Risk Of Hospitalization For Heart Failure

    Reuters – 12:31 PM ET 11/17/2019

    Eli Lilly and Co (LLY): * INTERIM ANALYSIS FROM EMPRISE REAL-WORLD STUDY SHOWS JARDIANCE® DECREASED RISK OF HOSPITALIZATION FOR HEART FAILURE COMPARED WITH DPP-4 INHIBITORS AND GLP-1 RECEPTOR AGONISTS Source text for Eikon: Further company coverage:

  18. Show article details.

    Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

    PR Newswire – 10:50 AM ET 11/17/2019

    RIDGEFIELD, Conn. and INDIANAPOLIS  A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty real-world study on effectiveness shows that Jardiance® was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists.

  19. Show article details.

    Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

    PR Newswire – 5:07 PM ET 11/13/2019

    RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes.

  20. Show article details.

    FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

    Reuters – 3:56 PM ET 11/13/2019

    Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co (LLY) and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes. The drug, empagliflozin, was approved in 2014 in doses of 10 mg and 20 mg to help lower blood sugar levels in patients with type 2 diabetes and is marketed as Jardiance.

Page:

Today's and Upcoming Events

  • Jan
    30

    LLY to announce Q4 earnings (Confirmed)

Past Events (last 90 days)

  • Nov
    14

    LLY ex-Dividend for $0.65 on 11/14/2019

    • Announce Date: 10/21/2019
    • Record Date: 11/15/2019
    • Pay Date: 12/10/2019
  • Oct
    23

    LLY announced Q3 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.